Clinical Trial Update: Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects [Phase 1]

View source ↗

Summary

This phase 1 clinical trial update reports on using the radioiodinated imaging agent [123I] AV39 with SPECT to assess protein disposition in subjects with Alzhe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [123I] AV39 (AV39 imaging agent (radioiodinated))

Snippet

Sponsor: Molecular NeuroImaging | Conditions: Alzheimers Disease | Phase 1 | Status: COMPLETED